.jpg)
.jpg)
.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Novo is paying up to $1 billion for a “non-incretin” medicine that might boost W...
Four years into a Congressional probe of Big Pharma’s potential abuse of a 2017 ...
Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now ...
Kate Cronin, who took the marketing reins at Moderna in 2021 as it was skyrocket...
Human medicines European public assessment report (EPAR): Kevzara, sarilumab, Da...
CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opp...
Human medicines European public assessment report (EPAR): Nexavar, sorafenib, Da...
Human medicines European public assessment report (EPAR): Ofev, nintedanib, Date...
Human medicines European public assessment report (EPAR): Incruse Ellipta (previ...
Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause am...
Relmada Therapeutics’ attempts to see whether a magic mushroom extract could be ...
Human medicines European public assessment report (EPAR): Winrevair, Sotatercept...
Both deputy directors at the key FDA center that oversees regulation of cancer d...
The FDA granted marketing authorization of the first diagnostic test for chlamyd...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
EMA’s 30th anniversary scientific conference - Medicines, regulation and the fut...
Novo Nordisk snagged an obesity asset from China's United Laboratories for up to...
Want to stay on top of the science and politics driving biotech today? Sign up t...
Human medicines European public assessment report (EPAR): Rolufta Ellipta (previ...
This week on "The Top Line," we hear from Nada Hanafi, co-founder of MedTech Col...
Get your daily dose of health and medicine every weekday with STAT’s free newsle...
The FDA has rejected Milestone Pharmaceuticals’ application for approval of Card...
European Medicines Agency says risks of potentially fatal side effects from dona...